Biomedical Engineering Reference
In-Depth Information
consisting of autologous interleukin 2-transfected cancer cells: outcome of a phase I study.
Hum Gene Ther 10:983-993
222. Davis PB, Cooper MJ (2007) Vectors for airway gene delivery. AAPS J 9:E11-E17
223. Fewell JG, Matar MM, Rice JS, Brunhoeber E, Slobodkin G, Pence C, Worker M, Lewis DH,
Anwer K (2009) Treatment of disseminated ovarian cancer using nonviral interleukin-12
gene therapy delivered intraperitoneally. J Gene Med 11:718-728
224. Ohana P, Gofrit O, Ayesh S, Al-Sharef W, Mizrahi A, Birman T, Schneider T, Matouk I,
de Groot N, Tavdy E, Sidi AA, Hochberg A (2004) Regulatory sequences of the H19 gene
in DNA based therapy of bladder cancer. Gene Ther Mol Biol 8:181-192
225. Schaffert D, Kiss M, Rodl W, Shir A, Levitzki A, Ogris M, Wagner E (2011) Poly(I:C)-
mediated tumor growth suppression in EGF-receptor overexpressing tumors using EGF-
polyethylene glycol-linear polyethylenimine as carrier. Pharm Res 28:731-741
226. Shir A, Ogris M, Roedl W, Wagner E, Levitzki A (2011) EGFR-homing dsRNA activates
cancer targeted immune response and eliminates disseminated EGFR over-expressing tumors
in mice. Clin Cancer Res 17:1033-1043
227. Klutz K, Schaffert D, Willhauck MJ, Grunwald GK, Haase R, Wunderlich N, Zach C,
Gildehaus FJ, Senekowitsch-Schmidtke R, Goke B, Wagner E, Ogris M, Spitzweg C
(2011) Epidermal growth factor receptor-targeted (131)I-therapy of liver cancer following
systemic delivery of the sodium iodide symporter gene. Mol Ther 19:676-685
228. Kircheis R, Ostermann E, Wolschek MF, Lichtenberger C, Magin-Lachmann C, Wightman
L, Kursa M, Wagner E (2002) Tumor-targeted gene delivery of tumor necrosis factor-alpha
induces tumor necrosis and tumor regression without systemic toxicity. Cancer Gene Ther
9:673-680
229. Wagner E, Kircheis R, Walker GF (2004) Targeted nucleic acid delivery into tumors: new
avenues for cancer therapy. Biomed Pharmacother 58:152-161
230. Dufes C, Keith WN, Bilsland A, Proutski I, Uchegbu IF, Schatzlein AG (2005) Synthetic
anticancer gene medicine exploits intrinsic antitumor activity of cationic vector to cure
established tumors. Cancer Res 65:8079-8084
231. Bartlett DW, Davis ME (2008) Impact of tumor-specific targeting and dosing schedule on
tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles.
Biotechnol Bioeng 99:975-985
232. Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME (2007) Impact of tumor-specific
targeting on the biodistribution and efficacy of siRNA nanoparticles measured by
multimodality in vivo imaging. Proc Natl Acad Sci USA 104:15549-15554
233. Heidel JD, Yu Z, Liu JY, Rele SM, Liang Y, Zeidan RK, Kornbrust DJ, Davis ME (2007)
Administration in non-human primates of escalating intravenous doses of targeted nano-
particles containing ribonucleotide reductase subunit M2 siRNA. Proc Natl Acad Sci USA
104:5715-5721
234. Davis ME (2009) The first targeted delivery of siRNA in humans via a self-assembling,
cyclodextrin polymer-based nanoparticle: from concept
to clinic. Mol Pharmaceutics
6:659-668
235. Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD,
Ribas A (2010) Evidence of RNAi in humans from systemically administered siRNA via
targeted nanoparticles. Nature 464:1067-1070
236. Hartmann L, Hafele S, Peschka-Suss R, Antonietti M, Borner HG (2008) Tailor-made poly
(amidoamine)s
for controlled complexation and condensation of DNA. Chemistry
14:2025-2033
237. Schaffert D, Badgujar N, Wagner E (2011) Novel Fmoc-polyamino acids for solid-phase
synthesis of defined polyamidoamines. Org Lett 13:1586-1589
